{"id":5526,"date":"2019-02-28T11:56:00","date_gmt":"2019-02-28T11:56:00","guid":{"rendered":"https:\/\/www.adacyte.com\/?post_type=scientific-corner&#038;p=5526"},"modified":"2024-05-02T11:14:03","modified_gmt":"2024-05-02T09:14:03","slug":"granulomonocytapheresis-as-a-cell-dependent-treatment-option-for-patients-with-inflammatory-bowel-disease-concepts-and-clinical-features-for-better-therapeutic-outcomes","status":"publish","type":"scientific-corner","link":"https:\/\/www.adacyte.com\/es\/professional\/scientific-corner\/granulomonocytapheresis-as-a-cell-dependent-treatment-option-for-patients-with-inflammatory-bowel-disease-concepts-and-clinical-features-for-better-therapeutic-outcomes\/","title":{"rendered":"Granulomonocytapheresis as a cell-dependent treatment option for patients with inflammatory bowel disease: Concepts and clinical features for better therapeutic outcomes."},"content":{"rendered":"<div class=\"post-content max-w-987 mx-auto px-20 lg:px-0\">\n<p><a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/?term=Saniabadi+AR&amp;cauthor_id=30407662\">Abbi R Saniabadi<\/a><sup>&nbsp;<a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/30407662\/#affiliation-1\">1<\/a><\/sup>,&nbsp;<a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/?term=Tanaka+T&amp;cauthor_id=30407662\">Tomotaka Tanaka<\/a><sup>&nbsp;<a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/30407662\/#affiliation-2\">2<\/a><\/sup>,&nbsp;<a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/?term=Yamamoto+T&amp;cauthor_id=30407662\">Takayuki Yamamoto<\/a><sup>&nbsp;<a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/30407662\/#affiliation-3\">3<\/a><\/sup>,&nbsp;<a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/?term=Kruis+W&amp;cauthor_id=30407662\">Wolfgang Kruis<\/a><sup>&nbsp;<a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/30407662\/#affiliation-4\">4<\/a><\/sup>,&nbsp;<a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/?term=Sacco+R&amp;cauthor_id=30407662\">Rodolfo Sacco<\/a><sup>&nbsp;<a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/30407662\/#affiliation-5\">5<\/a><\/sup> , J Clin Apher 2019 Feb;34(1):51-60.&nbsp;<\/p>\n<\/div>\n\n<div class=\"post-content max-w-987 mx-auto px-20 lg:px-0\">\n<p>Accordingly, for responder patients, GMA fulfills a desire to be treated without drugs.<\/p>\n<\/div>\n\n<div class=\"post-content max-w-987 mx-auto px-20 lg:px-0\">\n<p><a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/30407662\/\" target=\"_blank\" rel=\"noreferrer noopener\">https:\/\/pubmed.ncbi.nlm.nih.gov\/30407662\/<\/a><\/p>\n<\/div>","protected":false},"excerpt":{"rendered":"<p>Abbi R Saniabadi&nbsp;1,&nbsp;Tomotaka Tanaka&nbsp;2,&nbsp;Takayuki Yamamoto&nbsp;3,&nbsp;Wolfgang Kruis&nbsp;4,&nbsp;Rodolfo Sacco&nbsp;5 , J Clin Apher 2019 Feb;34(1):51-60.&nbsp; Accordingly, for responder patients, GMA fulfills a desire to be treated without drugs. https:\/\/pubmed.ncbi.nlm.nih.gov\/30407662\/<\/p>\n","protected":false},"template":"","scientific_tags":[147,119,159,306],"class_list":["post-5526","scientific-corner","type-scientific-corner","status-publish","hentry","scientific_tags-clinical-remission","scientific_tags-complement","scientific_tags-crohns-disease","scientific_tags-ulcerative-colitis"],"acf":{"sc_authors":"<a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/30407662\/\">https:\/\/pubmed.ncbi.nlm.nih.gov\/30407662\/<\/a>"},"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v22.9 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Granulomonocytapheresis as a cell-dependent treatment option for patients with inflammatory bowel disease: Concepts and clinical features for better therapeutic outcomes. - Adacyte<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.adacyte.com\/professional\/scientific-corner\/granulomonocytapheresis-as-a-cell-dependent-treatment-option-for-patients-with-inflammatory-bowel-disease-concepts-and-clinical-features-for-better-therapeutic-outcomes\/\" \/>\n<meta property=\"og:locale\" content=\"es_ES\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Granulomonocytapheresis as a cell-dependent treatment option for patients with inflammatory bowel disease: Concepts and clinical features for better therapeutic outcomes. - Adacyte\" \/>\n<meta property=\"og:description\" content=\"Abbi R Saniabadi&nbsp;1,&nbsp;Tomotaka Tanaka&nbsp;2,&nbsp;Takayuki Yamamoto&nbsp;3,&nbsp;Wolfgang Kruis&nbsp;4,&nbsp;Rodolfo Sacco&nbsp;5 , J Clin Apher 2019 Feb;34(1):51-60.&nbsp; Accordingly, for responder patients, GMA fulfills a desire to be treated without drugs. https:\/\/pubmed.ncbi.nlm.nih.gov\/30407662\/\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.adacyte.com\/professional\/scientific-corner\/granulomonocytapheresis-as-a-cell-dependent-treatment-option-for-patients-with-inflammatory-bowel-disease-concepts-and-clinical-features-for-better-therapeutic-outcomes\/\" \/>\n<meta property=\"og:site_name\" content=\"Adacyte\" \/>\n<meta property=\"article:modified_time\" content=\"2024-05-02T09:14:03+00:00\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Tiempo de lectura\" \/>\n\t<meta name=\"twitter:data1\" content=\"1 minuto\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.adacyte.com\/professional\/scientific-corner\/granulomonocytapheresis-as-a-cell-dependent-treatment-option-for-patients-with-inflammatory-bowel-disease-concepts-and-clinical-features-for-better-therapeutic-outcomes\/\",\"url\":\"https:\/\/www.adacyte.com\/professional\/scientific-corner\/granulomonocytapheresis-as-a-cell-dependent-treatment-option-for-patients-with-inflammatory-bowel-disease-concepts-and-clinical-features-for-better-therapeutic-outcomes\/\",\"name\":\"Granulomonocytapheresis as a cell-dependent treatment option for patients with inflammatory bowel disease: Concepts and clinical features for better therapeutic outcomes. - Adacyte\",\"isPartOf\":{\"@id\":\"https:\/\/www.adacyte.com\/#website\"},\"datePublished\":\"2019-02-28T11:56:00+00:00\",\"dateModified\":\"2024-05-02T09:14:03+00:00\",\"inLanguage\":\"es\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.adacyte.com\/professional\/scientific-corner\/granulomonocytapheresis-as-a-cell-dependent-treatment-option-for-patients-with-inflammatory-bowel-disease-concepts-and-clinical-features-for-better-therapeutic-outcomes\/\"]}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.adacyte.com\/#website\",\"url\":\"https:\/\/www.adacyte.com\/\",\"name\":\"Adacyte\",\"description\":\"Adacyte Therapeutics\",\"publisher\":{\"@id\":\"https:\/\/www.adacyte.com\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.adacyte.com\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"es\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/www.adacyte.com\/#organization\",\"name\":\"Adacyte\",\"url\":\"https:\/\/www.adacyte.com\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"es\",\"@id\":\"https:\/\/www.adacyte.com\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/www.adacyte.com\/wp-content\/uploads\/2021\/01\/logo-adacyte.svg\",\"contentUrl\":\"https:\/\/www.adacyte.com\/wp-content\/uploads\/2021\/01\/logo-adacyte.svg\",\"width\":165,\"height\":46,\"caption\":\"Adacyte\"},\"image\":{\"@id\":\"https:\/\/www.adacyte.com\/#\/schema\/logo\/image\/\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Granulomonocytapheresis as a cell-dependent treatment option for patients with inflammatory bowel disease: Concepts and clinical features for better therapeutic outcomes. - Adacyte","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.adacyte.com\/professional\/scientific-corner\/granulomonocytapheresis-as-a-cell-dependent-treatment-option-for-patients-with-inflammatory-bowel-disease-concepts-and-clinical-features-for-better-therapeutic-outcomes\/","og_locale":"es_ES","og_type":"article","og_title":"Granulomonocytapheresis as a cell-dependent treatment option for patients with inflammatory bowel disease: Concepts and clinical features for better therapeutic outcomes. - Adacyte","og_description":"Abbi R Saniabadi&nbsp;1,&nbsp;Tomotaka Tanaka&nbsp;2,&nbsp;Takayuki Yamamoto&nbsp;3,&nbsp;Wolfgang Kruis&nbsp;4,&nbsp;Rodolfo Sacco&nbsp;5 , J Clin Apher 2019 Feb;34(1):51-60.&nbsp; Accordingly, for responder patients, GMA fulfills a desire to be treated without drugs. https:\/\/pubmed.ncbi.nlm.nih.gov\/30407662\/","og_url":"https:\/\/www.adacyte.com\/professional\/scientific-corner\/granulomonocytapheresis-as-a-cell-dependent-treatment-option-for-patients-with-inflammatory-bowel-disease-concepts-and-clinical-features-for-better-therapeutic-outcomes\/","og_site_name":"Adacyte","article_modified_time":"2024-05-02T09:14:03+00:00","twitter_card":"summary_large_image","twitter_misc":{"Tiempo de lectura":"1 minuto"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.adacyte.com\/professional\/scientific-corner\/granulomonocytapheresis-as-a-cell-dependent-treatment-option-for-patients-with-inflammatory-bowel-disease-concepts-and-clinical-features-for-better-therapeutic-outcomes\/","url":"https:\/\/www.adacyte.com\/professional\/scientific-corner\/granulomonocytapheresis-as-a-cell-dependent-treatment-option-for-patients-with-inflammatory-bowel-disease-concepts-and-clinical-features-for-better-therapeutic-outcomes\/","name":"Granulomonocytapheresis as a cell-dependent treatment option for patients with inflammatory bowel disease: Concepts and clinical features for better therapeutic outcomes. - Adacyte","isPartOf":{"@id":"https:\/\/www.adacyte.com\/#website"},"datePublished":"2019-02-28T11:56:00+00:00","dateModified":"2024-05-02T09:14:03+00:00","inLanguage":"es","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.adacyte.com\/professional\/scientific-corner\/granulomonocytapheresis-as-a-cell-dependent-treatment-option-for-patients-with-inflammatory-bowel-disease-concepts-and-clinical-features-for-better-therapeutic-outcomes\/"]}]},{"@type":"WebSite","@id":"https:\/\/www.adacyte.com\/#website","url":"https:\/\/www.adacyte.com\/","name":"Adacyte","description":"Adacyte Therapeutics","publisher":{"@id":"https:\/\/www.adacyte.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.adacyte.com\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"es"},{"@type":"Organization","@id":"https:\/\/www.adacyte.com\/#organization","name":"Adacyte","url":"https:\/\/www.adacyte.com\/","logo":{"@type":"ImageObject","inLanguage":"es","@id":"https:\/\/www.adacyte.com\/#\/schema\/logo\/image\/","url":"https:\/\/www.adacyte.com\/wp-content\/uploads\/2021\/01\/logo-adacyte.svg","contentUrl":"https:\/\/www.adacyte.com\/wp-content\/uploads\/2021\/01\/logo-adacyte.svg","width":165,"height":46,"caption":"Adacyte"},"image":{"@id":"https:\/\/www.adacyte.com\/#\/schema\/logo\/image\/"}}]}},"_links":{"self":[{"href":"https:\/\/www.adacyte.com\/es\/wp-json\/wp\/v2\/scientific-corner\/5526","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.adacyte.com\/es\/wp-json\/wp\/v2\/scientific-corner"}],"about":[{"href":"https:\/\/www.adacyte.com\/es\/wp-json\/wp\/v2\/types\/scientific-corner"}],"wp:attachment":[{"href":"https:\/\/www.adacyte.com\/es\/wp-json\/wp\/v2\/media?parent=5526"}],"wp:term":[{"taxonomy":"scientific_tags","embeddable":true,"href":"https:\/\/www.adacyte.com\/es\/wp-json\/wp\/v2\/scientific_tags?post=5526"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}